Publications
Detailed Information
Antituberculosis drug-induced liver injury in chronic hepatitis and cirrhosis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Wan Beom | - |
dc.contributor.author | Kim, Won | - |
dc.contributor.author | Lee, Kook Lae | - |
dc.contributor.author | Yim, Jae-Joon | - |
dc.contributor.author | Jung, Yong Jin | - |
dc.contributor.author | Kim, Dong Hee | - |
dc.contributor.author | Yoon, Jung-Hwan | - |
dc.contributor.author | Lee, Hyo Suk | - |
dc.contributor.author | Oh, Myoung-don | - |
dc.contributor.author | Kim, Yoon Jun | - |
dc.contributor.author | Kim, Nam Joong | - |
dc.contributor.author | Kim, Moonsuk | - |
dc.date.accessioned | 2012-06-28T06:36:29Z | - |
dc.date.available | 2012-06-28T06:36:29Z | - |
dc.date.issued | 2010-10 | - |
dc.identifier.citation | JOURNAL OF INFECTION; Vol.61 4; 323-329 | ko_KR |
dc.identifier.issn | 0163-4453 | - |
dc.identifier.uri | https://hdl.handle.net/10371/77788 | - |
dc.description.abstract | Objectives: To evaluate the incidence, risk factors and outcomes for anti-tuberculosis (TB) drug-induced liver injury (DILI) in patients with chronic liver disease including cirrhosis. Methods: A total of 107 patients with chronic liver disease were assessed for anti-TB DILI. Anti-TB DILI was defined as elevation of alkaline phosphatase (ALP), aspartate transaminase, or alanine transaminase, or an increase in Child-Turcotte-Pugh score within 2 months of initiating anti-TB medication. The risk factors for anti-TB DILI were evaluated by multivariate logistic regression analysis. Results: Fifty-eight (54%) patients had cirrhosis. Of 93 patients receiving one or more hepatotoxic anti-TB drugs, 18 (17%) experienced DILI: 11 (24%) among 46 patients with chronic hepatitis and 7 (15%) among 46 patients with compensated liver cirrhosis (P = 0.271). Independent risk factors for DILI were female sex, number of hepatotoxic anti-TB drugs administered and baseline ALP levels but not cirrhosis itself. Of the 18 patients with DILI, 13 (72%) successfully completed anti-TB treatment after switching to less hepatotoxic drug regimens. Conclusions: Hepatotoxic anti-TB drugs may be safely used in the patients with chronic liver disease including compensated cirrhosis if number of hepatotoxic drugs used is adjusted appropriately. (C) 2010 The British Infection Society. Published by Elsevier Ltd. All rights reserved. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | W B SAUNDERS CO LTD | ko_KR |
dc.subject | Tuberculosis | ko_KR |
dc.subject | Chronic hepatitis | ko_KR |
dc.subject | Liver disease | ko_KR |
dc.subject | Cirrhosis | ko_KR |
dc.subject | Drug toxicity | ko_KR |
dc.title | Antituberculosis drug-induced liver injury in chronic hepatitis and cirrhosis | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 박완범 | - |
dc.contributor.AlternativeAuthor | 김원 | - |
dc.contributor.AlternativeAuthor | 이국래 | - |
dc.contributor.AlternativeAuthor | 임재준 | - |
dc.contributor.AlternativeAuthor | 김문숙 | - |
dc.contributor.AlternativeAuthor | 정용진 | - |
dc.contributor.AlternativeAuthor | 김남중 | - |
dc.contributor.AlternativeAuthor | 김동희 | - |
dc.contributor.AlternativeAuthor | 김윤준 | - |
dc.contributor.AlternativeAuthor | 윤정환 | - |
dc.contributor.AlternativeAuthor | 오명돈 | - |
dc.contributor.AlternativeAuthor | 이효숙 | - |
dc.identifier.doi | 10.1016/j.jinf.2010.07.009 | - |
dc.citation.journaltitle | JOURNAL OF INFECTION | - |
dc.description.citedreference | Gupta NK, 2008, ALIMENT PHARM THER, V28, P1021, DOI 10.1111/j.1365-2036.2008.03822.x | - |
dc.description.citedreference | Huang YS, 2007, J HEPATOL, V47, P128, DOI 10.1016/j.jhep.2007.02.009 | - |
dc.description.citedreference | Cho YJ, 2007, RESPIROLOGY, V12, P401, DOI 10.1111/j.1400-1843.2007.01069.x | - |
dc.description.citedreference | Saukkonen JJ, 2006, AM J RESP CRIT CARE, V174, P935, DOI 10.1164/rccm.200510-1666ST | - |
dc.description.citedreference | NATHWANI RA, 2006, CLIN LIVER DIS, V10, P207 | - |
dc.description.citedreference | Pan L, 2005, WORLD J GASTROENTERO, V11, P2518 | - |
dc.description.citedreference | Lee BH, 2005, CHEST, V127, P1304 | - |
dc.description.citedreference | BLUMBERG HM, 2003, AM J RESP CRIT CARE, V167, P603 | - |
dc.description.citedreference | Teleman MD, 2002, INT J TUBERC LUNG D, V6, P699 | - |
dc.description.citedreference | Huang YS, 2002, HEPATOLOGY, V35, P883, DOI 10.1053/jhep.2002.32102 | - |
dc.description.citedreference | Williams GM, 2002, TOXICOL PATHOL, V30, P41 | - |
dc.description.citedreference | Dunlap NE, 2000, AM J RESP CRIT CARE, V161, P1376 | - |
dc.description.citedreference | Wong WM, 2000, HEPATOLOGY, V31, P201 | - |
dc.description.citedreference | Ungo JR, 1998, AM J RESP CRIT CARE, V157, P1871 | - |
dc.description.citedreference | Hwang SJ, 1997, J GASTROEN HEPATOL, V12, P87 | - |
dc.description.citedreference | Schaberg T, 1996, EUR RESPIR J, V9, P2026 | - |
dc.description.citedreference | Dossing M, 1996, TUBERCLE LUNG DIS, V77, P335 | - |
dc.description.citedreference | DESMET VJ, 1994, HEPATOLOGY, V19, P1513 | - |
dc.description.citedreference | GUMBRECHT JR, 1983, DRUG METAB DISPOS, V11, P312 | - |
dc.description.citedreference | GRONHAGENRISKA C, 1978, AM REV RESPIR DIS, V118, P461 | - |
dc.description.citedreference | KOPANOFF DE, 1978, AM REV RESPIR DIS, V117, P991 | - |
dc.description.citedreference | MITCHELL JR, 1976, ANN INTERN MED, V84, P181 | - |
dc.description.citedreference | PUGH RNH, 1973, BRIT J SURG, V60, P646 | - |
dc.description.tc | 1 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.